Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for NK-cell therapy in acute myeloid leukemia

In conclusion, the modification of the DNAM-1/CD112 axis in NK cells may be an effective novel immunotherapy for AML. Furthermore, these results suggest the potential of the expression levels of these molecules as prognostic markers in AML.PMID:37731380 | DOI:10.3324/haematol.2023.282915

Source: Haematologica - September 21, 2023 Category: Hematology Authors: Yuta Kaito Emi Sugimoto Fumi Nakamura Yutaka Tsukune Makoto Sasaki Shunsuke Yui Hiroki Yamaguchi Susumu Goyama Yasuhito Nannya Kinuko Mitani Hideto Tamura Yoichi Imai Source Type: research